In addition, given that the MB49 and C57BL/6 models share similarities with human bladder cancer regarding cell surface markers, sensitivity to apoptosis and immunological profiles (16, 17), our findings lend plausibility to studying whether human patients with late stage bladder cancer have reduced VIP expression in serum compared to those with early stage disease. This evidence concerns the gene VIP and urinary bladder cancer.